These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33541027)

  • 1. [Advances on the management of renal lesion in glycogen storage disease type I].
    Wu WC; Wang JS
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):75-78. PubMed ID: 33541027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifiable factors affecting renal preservation in type I glycogen storage disease after liver transplantation: a single-center propensity-match cohort study.
    Chan YC; Liu KM; Chen CL; Ong AD; Lin CC; Yong CC; Tsai PC; Lu LS; Wu JY
    Orphanet J Rare Dis; 2021 Oct; 16(1):423. PubMed ID: 34635148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment.
    Chen YT
    Pediatr Nephrol; 1991 Jan; 5(1):71-6. PubMed ID: 2025544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal disease in an adult with type 1 glycogen storage disease.
    Kiyama S; Kitamoto Y; Nakayama M; Fukui H; Arima S; Tomita M; Inoue T; Sato T
    Nihon Jinzo Gakkai Shi; 1991 Jan; 33(1):81-5. PubMed ID: 2038136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfiltration and renal disease in glycogen storage disease, type I.
    Baker L; Dahlem S; Goldfarb S; Kern EF; Stanley CA; Egler J; Olshan JS; Heyman S
    Kidney Int; 1989 Jun; 35(6):1345-50. PubMed ID: 2671467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 genome editing of SLC37A4 gene elucidates the role of molecular markers of endoplasmic reticulum stress and apoptosis in renal involvement in glycogen storage disease type Ib.
    Skakic A; Andjelkovic M; Tosic N; Klaassen K; Djordjevic M; Pavlovic S; Stojiljkovic M
    Gene; 2019 Jun; 703():17-25. PubMed ID: 30951856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.
    Clar J; Gri B; Calderaro J; Birling MC; Hérault Y; Smit GP; Mithieux G; Rajas F
    Kidney Int; 2014 Oct; 86(4):747-56. PubMed ID: 24717294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-6-phosphatase deficiency.
    Froissart R; Piraud M; Boudjemline AM; Vianey-Saban C; Petit F; Hubert-Buron A; Eberschweiler PT; Gajdos V; Labrune P
    Orphanet J Rare Dis; 2011 May; 6():27. PubMed ID: 21599942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies for glycogen storage disease type I.
    Koeberl DD; Kishnani PS; Bali D; Chen YT
    Trends Endocrinol Metab; 2009 Jul; 20(5):252-8. PubMed ID: 19541498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension in a child with type IA glycogen storage disease.
    Jonas AJ; Verani RR; Howell RR; Conley SB
    Am J Kidney Dis; 1988 Mar; 11(3):264-6. PubMed ID: 3422787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biology and gene therapy for glycogen storage disease type Ib.
    Chou JY; Cho JH; Kim GY; Mansfield BC
    J Inherit Metab Dis; 2018 Nov; 41(6):1007-1014. PubMed ID: 29663270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation.
    Matern D; Seydewitz HH; Bali D; Lang C; Chen YT
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S10-9. PubMed ID: 12373566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercalcemia in glycogen storage disease type I patients of Turkish origin.
    Kasapkara CS; Tümer L; Okur I; Eminoğlu T; Ezgü FS; Hasanoğlu A
    Turk J Pediatr; 2012; 54(1):35-7. PubMed ID: 22397040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.
    Chou JY; Matern D; Mansfield BC; Chen YT
    Curr Mol Med; 2002 Mar; 2(2):121-43. PubMed ID: 11949931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal complications in glycogen storage disease type I.
    Reitsma-Bierens WC
    Eur J Pediatr; 1993; 152 Suppl 1():S60-2. PubMed ID: 8319728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
    Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
    J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal endoplasmic reticulum stress is coupled to impaired autophagy in a mouse model of GSD Ia.
    Farah BL; Landau DJ; Wu Y; Sinha RA; Loh A; Bay BH; Koeberl DD; Yen PM
    Mol Genet Metab; 2017 Nov; 122(3):95-98. PubMed ID: 28888852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for type I glycogen storage diseases.
    Chou JY; Mansfield BC
    Curr Gene Ther; 2007 Apr; 7(2):79-88. PubMed ID: 17430128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early diagnosis and treatment may prevent the development of complications in an adult patient with glycogen storage disease type Ia.
    Araoka T; Takeoka H; Abe H; Kishi S; Araki M; Nishioka K; Ikeda M; Mazaki T; Ikemura S; Kondo M; Hoshina A; Nagai K; Mima A; Murakami T; Mimura R; Oka K; Saito T; Doi T
    Intern Med; 2010; 49(16):1787-92. PubMed ID: 20720360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
    Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
    Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.